Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02776917
• Other study ID #: 160178
• Status: Completed
• Phase: Phase 1
• Start date: August 15, 2018
• Est. completion date: February 26, 2024

Study information

• Verified date: April 2024
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot phase 1b study to investigate the safety and side effects of combining the ROR1-targeting monoclonal antibody, cirmtuzumab, with paclitaxel for patients with HER2 negative, metastatic breast cancer. Cirmtuzumab is a type of drug called a monoclonal antibody. This drug is designed to attach to a protein called receptor-tyrosine-kinase like orphan receptor 1 (ROR1) on the surface of breast cancer cells. Cirmtuzumab blocks the growth and survival of the breast cancer cells in laboratory tests. ROR1 is rarely expressed on healthy cells. Cirmtuzumab is considered experimental and is not approved by United States (U.S.) Food and Drug Administration (FDA).

Description:

• This is a phase 1b, open-label, non-randomized, fixed dose study in patients with HER2 negative metastatic, or locally advanced, unresectable breast cancer.

• Cirmtuzumab and paclitaxel will be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity, as long as the subject is tolerating the drug and does not exhibit disease progression.

• Blood and tissue samples will be collected at pre-specified times to enable pharmacokinetic and correlative studies.

• Adverse events (AE) will be monitored throughout the trial. Reporting of AEs will be in accordance with CTCAE version 4.03.

• Assessment of tumor response will be performed by physical examination and/or by radiographic imaging and according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.

• Patients will be assessed at 28 days following the last dose of cirmtuzumab to assess tumor response and at 56 days following the last dose of cirmtuzumab to assess any adverse events and to document any concomitant cancer therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 26, 2024
• Est. primary completion date: July 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

• Biopsy-confirmed, metastatic or locally advanced surgically unresectable, HER2 negative breast cancer. HER2 status should reflect the most recent biopsy results. Note: HER2 negative breast cancer is defined according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines 2013 for HER2 testing performed in a CLIA-certified laboratory.

• ER/PR negative (<10% of cells staining for ER or PR) breast cancer or have ER/PR positive (=10% of cells staining for ER or PR) breast cancer that has exhausted standard endocrine therapy and/or in the opinion of the treating oncologist, warrants cytotoxic chemotherapy.

• Measurable disease as defined by RECIST v1.1. Measurable lesions will be confirmed by radiographic imaging (CT or MRI). Patients with bone only disease will be eligible if disease is considered measurable and a soft tissue component is present and can be biopsied..

• There is no limit to prior lines of therapy, but patients must not have received prior taxane chemotherapy in the metastatic setting.

• ECOG Performance Status = 2.

• Adequate organ function as defined below:

• Absolute Neutrophil Count = 1.0 x 10^9/L

• Platelet count = 100,000 /µL

• Hemoglobin = 8.0 g/dL

• Total bilirubin = 1.5 x upper limit of normal

• AST and ALT = 3 x upper limit of normal

• Serum creatinine = 2 x upper limit of normal OR Creatinine clearance > 40 ml/min/1.73 m^2

• Women of child-bearing potential and male subjects who are sexually active with a woman of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months following last infusion of cirmtuzumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• Existing neuropathy must be no greater than Grade 1.

• No concurrent antibody therapy can be planned with the exception of denosumab for use in bone metastasis.

• CNS metastases are allowed as long as the metastases are asymptomatic, have been treated with radiation, and have been stable for > 6 weeks off steroids.

EXCLUSION CRITERIA:

• Patient is currently receiving chemotherapy or has received another chemotherapy within 5 half-lives, radiotherapy or immunotherapy within 2 weeks prior to study treatment initiation.

• Patient has known, untreated and/or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Patient had disease that was refractory to paclitaxel in the neoadjuvant setting and/or developed metastatic breast cancer within 6 months of neoadjuvant or adjuvant taxane chemotherapy.

• Patient has had major surgery within 3 weeks prior to enrollment.

• Patient has severe and/or uncontrolled medical disease(s) (i.e., myocardial infarction within 6 months of study, CKD stage IV or above, severe chronic pulmonary disease or active infection).

• The patient has known acute or chronic hepatitis B or C.

• The patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel.

• The patient has a history of another malignancy within 2 years prior to study entry, except curatively treated non-melanotic skin cancer, cervical carcinoma in situ or stage I colon cancer.

• Patient has a history of non-compliance or other medical illness that would preclude compliance with study procedures.

• Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

• Patient has severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable cardiac or coronary artery disease

• Patient is pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants.

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Drug:
• Cirmtuzumab + Paclitaxel
Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.

Locations

Country	Name	City	State
United States	University of California, San Diego	La Jolla	California

Sponsors (2)

Lead Sponsor	Collaborator
Barbara Parker, MD	Oncternal Therapeutics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlates of PET/CT and cross-sectional imaging	Comparison of PET/CT results with standard cross-sectional imaging	9 months
Other	Assessment of mechanism of action through pharmacokinetic studies	Measurement of plasma pharmacokinetics of cirmtuzumab and level of circulating antibody formation against cirmtuzumab; gene expression and functional studies of stem-like cells in tumor tissue as available	9 months
Primary	The rate of dose-limiting toxicities during the first 4 weeks of treatment	The proportion of clinically significant adverse events per CTCAE Version 4.03 at least possibly related to cirmtuzumab or the combination of cirmtuzumab and paclitaxel during the first four weeks of investigational treatment.	Within 4 weeks of starting study treatment
Secondary	Safety and tolerability of the combination therapy since the start of any study treatment.	Treatment-emergent adverse events beginning from the start of study treatment to six months after study treatment completion.	12 months
Secondary	Objective tumor response rate	The proportion of patients with complete and partial tumor responses as assessed by RECIST v1.1	9 months
Secondary	Best tumor response rate	The proportion of patients that achieve a response of stable disease or better as assessed by RECIST v1.1	9 months
Secondary	Time to progression	The duration of response measured from the time of initial response until documented tumor progression.	2 years
Secondary	Measurement of ROR1 expression levels and cancer stem cell populations	Immunohistochemistry measurement of ROR1 expression levels and other cancer stem cell markers (ALDH, CD133) from primary pre-treatment and post-treatment tumor specimens.	12 months